Thymosin α1 plus routine treatment inhibit inflammatory reaction and improve the quality of life in AECOPD patients

Immunopharmacology and Immunotoxicology

Volumn 37, Issue 4, 2015, Pages 388-392

  Jia, Zhiyang ^a   Feng, Zihui ^a   Tian, Rui ^a   Wang, Qian ^a   Wang, Linyu ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

Acute exacerbation of chronic obstructive pulmonary disease; COPD; immune function; routine treatment; thymosin 1

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 4; LEUKOTRIENE B4; OXYGEN; THYMOSIN ALPHA1; ANTIINFECTIVE AGENT; CYTOKINE; IMMUNOLOGICAL ADJUVANT; THYMOSIN;

AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; HUMAN; HUMAN CELL; INFLAMMATION; LUNG FUNCTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRESSURE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; T LYMPHOCYTE SUBPOPULATION; ANALOGS AND DERIVATIVES; BLOOD; COMBINATION DRUG THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; IMMUNOLOGY; LUNG FUNCTION TEST; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; AGED; ANTI-BACTERIAL AGENTS; CYTOKINES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTE SUBSETS; THYMOSIN; TREATMENT OUTCOME;

EID: 84938845797     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923973.2015.1069837     Document Type: Article

References (18)

1. Rabe KF, Hurd S, Anzueto A, et al. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-555.
2. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet 2012;379:1341-1351.
3. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir 2003;22:668-672.
4. Limón-Camacho L, Solleiro-Villavicencio H, Pupko-Sissa I, et al. Regulatory T cells in chronic obstructive pulmonary disease. Arch Cardiol Mex 2013;83:45-54.
5. Faner R, Cruz T, Agusti A. Immune response in chronic obstructive pulmonary disease. Expert Rev Clin Immunol 2013;9:821-833.
6. Wang C, Liu X, Peng Q, et al. Role of Foxp3/Treg and RORγt/Th17 cell imbalance in rat model of chronic obstructive pulmonary disease. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2014;26:860-864.
7. Stefanska AM, Walsh PT. Chronic obstructive pulmonary disease: evidence for an autoimmune component. Cell Mol Immunol 2009;6:81-86.
8. Hou F, Huang JM, Zhang R, et al. An experimental study on the regulation of bone marrow-derived mesenchymal stem cells through indoleamine 2,3-dioxygenase signaling pathway by thymosin α1 for improving the immunosuppression mediated by T cell. Zhonghua Er Ke Za Zhi 2011;49:181-185.
9. Romani L, Bistoni F, Montagnoli C, et al. Thymosin alpha 1: an endogenous regulator of inflammation, immunity, and tolerance. Ann NY Acad Sci 2007;1112:326-338.
10. Zheng BX, Cheng DY, Xu G, et al. The prophylactic effect of thymosin alpha 1 on the acute exacerbation of chronic obstructive pulmonary disease. Sichuan Da Xue Xue Bao Yi Xue Ban 2008;39:588-590.
11. Chronic Obstructive Pulmonary Disease Committee, Respiratory Society, Chinese Medical Association. Diagnosed standards of chronic obstructive pulmonary disease (the 2007 revision). Zhonghua Jie He He Hu Xi Za Zhi 2007;30:8-17 (In Chinese).
12. Fukuhara S, Bito S, Green J, et al. Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J Clin Epidemiol 1998;51:1037-1044.
13. Chilvers ER, Cadwallader KA, Reed BJ, et al. The function and fate of neutrophils at the inflamed site: prospects for therapeutic intervention. J R Coll Physicians Lond 2000;34:68-74.
14. Rubin P, Mollison KW. Pharmacotherapy of diseases mediated by 5-lipoxygenase pathway eicosanoids. Prostaglandins Other Lipid Mediat 2007;83:188-197.
15. Beeh KM, Kornmann O, Buhl R, et al. Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. Chest 2003;123:1240-1247.
16. Pierluigi B, D'Angelo C, Fallarino F, et al. Thymosin alpha 1: the regulator of regulators? Ann NY Acad Sci 2010;1194:1-5.
17. Chang C, Yao W. Time course of inflammation resolution in patients with frequent exacerbations of chronic obstructive pulmonary disease. Med Sci Monit 2014;20:311-320.
18. Bathoorn E, Kerstjens H, Postma D, et al. Airways inflammation and treatment during acute exacerbations of COPD. Int J Chron Obstruct Pulmon Dis 2008;3:217-229.